

Silvia Montoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3835482/publications.pdf>

Version: 2024-02-01

217
papers

10,260
citations

39113

52
h-index

45040

94
g-index

222
all docs

222
docs citations

222
times ranked

10685
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. <i>Haematologica</i> , 2022, 107, 1054-1063.	1.7	20
2	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	2.5	16
3	The first steps towards a diverse and inclusive EBMT: a position paper. <i>Bone Marrow Transplantation</i> , 2022, 57, 343-346.	1.3	2
4	Follicular lymphoma: life beyond the third line. <i>Lancet Haematology</i> , 2022, 9, e241-e242.	2.2	0
5	Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients. <i>Clinical Infectious Diseases</i> , 2022, 75, 178-179.	2.9	9
6	The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. <i>Leukemia</i> , 2022, 36, 1646-1653.	3.3	6
7	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3541.	1.0	4
8	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party's EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 655-663.	1.3	7
9	Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S�azary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1391-1401.	1.3	24
10	Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1413-1421.	1.3	9
11	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	0.6	53
12	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. <i>Lancet Haematology</i> , 2021, 8, e205-e215.	2.2	26
13	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	0.8	37
14	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	2.5	24
15	Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. <i>European Journal of Cancer</i> , 2021, 157, 132-139.	1.3	4
16	Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party's EBMT. <i>British Journal of Haematology</i> , 2021, . .	1.2	2
17	Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 317-324.	1.3	13
18	Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 393-399.	1.3	29

#	ARTICLE	IF	CITATIONS
19	Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. <i>Bone Marrow Transplantation</i> , 2020, 55, 613-622.	1.3	15
20	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	1.3	196
21	Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 796-803.	1.3	9
22	Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 633-640.	1.3	5
23	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study. <i>British Journal of Haematology</i> , 2020, 188, 745-756.	1.2	20
24	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 884-890.	1.3	13
25	Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e77-e85.	2.0	41
26	Treatment management of haematological malignancies in people living with HIV. <i>Lancet Haematology</i> , 2020, 7, e679-e689.	2.2	18
27	Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI ≥ 5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. <i>Annals of Oncology</i> , 2020, 31, 1251-1259.	0.6	41
28	Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT. <i>Leukemia and Lymphoma</i> , 2020, 61, 2915-2922.	0.6	1
29	Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 2170-2179.	1.3	8
30	Clinical outcome of coronavirus disease 2019 in haematology patients. <i>British Journal of Haematology</i> , 2020, 190, e64-e67.	1.2	81
31	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. <i>Bone Marrow Transplantation</i> , 2020, 55, 2071-2076.	1.3	163
32	Favourable outcomes for high-risk Burkitt lymphoma patients (IPI ≥ 5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial. <i>EJHaem</i> , 2020, 1, 133-141.	0.4	5
33	Cellular Therapy in Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 701-714.	0.9	1
34	The investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 363-381.	1.2	14
35	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , 2020, 38, 1518-1526.	0.8	34
36	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Ts come into focus. <i>Bone Marrow Transplantation</i> , 2020, 55, 1604-1613.	1.3	147

#	ARTICLE	IF	CITATIONS
37	Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 2335-2338.	1.3	3
38	How much has allogeneic stem cell transplantâ€™related mortality improved since the 1980s? A retrospective analysis from the EBMT. <i>Blood Advances</i> , 2020, 4, 6283-6290.	2.5	89
39	Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance. <i>Blood</i> , 2020, 136, 1-2.	0.6	2
40	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020, 136, 49-50.	0.6	1
41	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020, 136, 46-49.	0.6	0
42	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. <i>Bone Marrow Transplantation</i> , 2019, 54, 44-52.	1.3	59
43	Biosimilar drugs: how safe are they?. <i>Leukemia and Lymphoma</i> , 2019, 60, 3343-3344.	0.6	1
44	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2060-2071.	1.3	6
45	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , the, 2019, 6, e573-e584.	2.2	140
46	Localized FL: how long in response to be cured?. <i>Blood</i> , 2019, 133, 187-188.	0.6	1
47	Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2013-2019.	1.3	21
48	The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. <i>Annals of Hematology</i> , 2019, 98, 1755-1763.	0.8	35
49	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	1.3	218
50	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. <i>Bone Marrow Transplantation</i> , 2019, 54, 1575-1585.	1.3	129
51	Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2019, 54, 1625-1631.	1.3	11
52	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	3.4	44
53	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019, 3, 360-369.	2.5	92
54	DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT-LWP STUDY. <i>Hematological Oncology</i> , 2019, 37, 316-317.	0.8	0

#	ARTICLE	IF	CITATIONS
55	The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 86-93.	2.0	21
56	Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 562-564.	0.6	1
57	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , 2019, 125, 90-98.	2.0	15
58	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	0.6	6
59	From Ex-Vivo T-Cell Depletion to Post-Transplant Cyclophosphamide: Improved GvHD-Free & Relapse-Free Survival but Comparable Chronic GvHD Incidence in Haploidentical Transplantation. A 15 Years EBMT Registry Analysis on Behalf of the TCWP-EBMT. <i>Blood</i> , 2019, 134, 876-876.	0.6	0
60	The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 43-43.	0.6	0
61	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1001-1009.	1.3	23
62	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. <i>British Journal of Haematology</i> , 2018, 181, 86-96.	1.2	23
63	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology</i> , 2018, 5, e190-e200.	2.2	50
64	Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. <i>Leukemia</i> , 2018, 32, 1261-1265.	3.3	87
65	Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2018, 53, 617-624.	1.3	45
66	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. <i>Cancer</i> , 2018, 124, 1733-1742.	2.0	58
67	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1548-1552.	1.3	6
68	Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018, 181, 760-769.	1.2	49
69	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018, 103, 1191-1197.	1.7	90
70	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018, 53, 1139-1148.	1.3	117
71	Treating relapsed follicular lymphoma. <i>Expert Review of Hematology</i> , 2018, 11, 403-410.	1.0	3
72	High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation lymphoma working party. <i>American Journal of Hematology</i> , 2018, 93, 40-46.	2.0	19

#	ARTICLE	IF	CITATIONS
73	Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. <i>Lancet Haematology</i> , 2018, 5, e359-e367.	2.2	74
74	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and GITMO. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	1.2	19
75	Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2265-2270.	2.0	10
76	Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma. <i>Cancer</i> , 2018, 124, 3455-3456.	2.0	0
77	High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2018, 53, 1553-1559.	1.3	22
78	Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD) reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTR and EBMT analysis. <i>Journal of Clinical Oncology</i> , 2018, 36, 7056-7056.	0.8	2
79	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646.	0.8	7
80	DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST-AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12-YEAR FOLLOW-UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL. <i>Hematological Oncology</i> , 2017, 35, 32-33.	0.8	4
81	High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. <i>Bone Marrow Transplantation</i> , 2017, 52, 1268-1272.	1.3	18
82	Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2017, 52, 1120-1125.	1.3	8
83	Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2017, 52, 811-817.	1.3	310
84	Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience. <i>Bone Marrow Transplantation</i> , 2017, 52, 650-652.	1.3	25
85	Role of stem cell transplant in lymphoma in the era of new drugs. <i>Current Opinion in Oncology</i> , 2017, 29, 455-459.	1.1	10
86	THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA TRANSFORMED BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE. <i>Hematological Oncology</i> , 2017, 35, 115-116.	0.8	8
87	CHOP VERSUS GEM-P IN THE FIRST-LINE TREATMENT OF T-CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NCRI PHASE II RANDOMISED CHEMO-T TRIAL. <i>Hematological Oncology</i> , 2017, 35, 75-76.	0.8	3
88	BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY. <i>Hematological Oncology</i> , 2017, 35, 83-84.	0.8	0
89	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) FOR PATIENTS WITH RELAPSED/REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (R/R SALCL). A RETROSPECTIVE ANALYSIS OF THE LYMPHOMA WORKING PARTY-EBMT. <i>Hematological Oncology</i> , 2017, 35, 242-243.	0.8	0
90	THE ROLE OF 18F FDG-PET/CT IN PERIPHERAL T-CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NCRI MULTICENTRE PHASE II RANDOMISED CHEMO-T TRIAL PET/CT SUBSTUDY. <i>Hematological Oncology</i> , 2017, 35, 244-245.	0.8	0

#	ARTICLE	IF	CITATIONS
91	APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2017, 35, 156-157.	0.8	0
92	CAR-T cells: the narrow path between hope and bankruptcy?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1588-1589.	1.3	24
93	Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 3425-3432.	0.8	132
94	The routes for transformation of follicular lymphoma. <i>Current Opinion in Hematology</i> , 2016, 23, 385-391.	1.2	16
95	Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. <i>Leukemia</i> , 2016, 30, 2086-2089.	3.3	45
96	Reply to the letter to the editor "Survival in young adults diagnosed with follicular lymphoma" by Calvo et al.. <i>Annals of Oncology</i> , 2016, 27, 1173.	0.6	0
97	Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT. <i>Annals of Oncology</i> , 2016, 27, 1088-1094.	0.6	29
98	Recurrent mTORC1-activating RRAC mutations in follicular lymphoma. <i>Nature Genetics</i> , 2016, 48, 183-188.	9.4	160
99	Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial. <i>Blood</i> , 2016, 128, 1855-1855.	0.6	6
100	Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT. <i>Blood</i> , 2016, 128, 4657-4657.	0.6	7
101	Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)-a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 4661-4661.	0.6	1
102	Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 514-514.	0.6	1
103	HIV-Associated Hodgkin Lymphoma. , 2016, , 119-132.		1
104	Treatment of patients with transformed lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 625-630.	0.9	15
105	Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. <i>Aids</i> , 2015, 29, 903-910.	1.0	29
106	Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. <i>Cancer</i> , 2015, 121, 423-431.	2.0	34
107	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
108	Life expectancy of young adults with follicular lymphoma. <i>Annals of Oncology</i> , 2015, 26, 2317-2322.	0.6	31

#	ARTICLE	IF	CITATIONS
109	Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. <i>Bone Marrow Transplantation</i> , 2015, 50, 197-203.	1.3	37
110	CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8552-8552.	0.8	4
111	Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. <i>Bone Marrow Transplantation</i> , 2014, 49, 1360-1365.	1.3	87
112	The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. <i>Annals of Oncology</i> , 2014, 25, 2224-2229.	0.6	23
113	The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma. <i>Nuclear Medicine Communications</i> , 2014, 35, 311-315.	0.5	15
114	Central nervous system prophylaxis in patients with diffuse large B cell lymphoma, are we treating ourselves? A response to the recent BCSH Guideline " response to Griffin <i>et al</i>. <i>British Journal of Haematology</i> , 2014, 167, 579-580.	1.2	0
115	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. <i>Nature Genetics</i> , 2014, 46, 176-181.	9.4	624
116	Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality. <i>Journal of Clinical Oncology</i> , 2014, 32, 273-281.	0.8	133
117	[¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1769-1775.	0.8	149
118	Managing HIV and Hodgkin Lymphoma in the Twenty-first century. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 227-232.	1.2	5
119	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.	2.0	119
120	HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. <i>Aids</i> , 2014, 28, 689-697.	1.0	53
121	Early rituximab failure (ERF) in relapsed diffuse large b-cell lymphoma (DLBCL) and prediction of futility of autologous hematopoietic cell transplantation (AHCT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7048-7048.	0.8	0
122	A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1921-1927.	0.6	2
123	Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 746-753.	2.0	83
124	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	0.6	193
125	Hematopoietic Stem Cell Transplantation in Patients with Lymphomatoid Granulomatosis: A European Group for Blood and Marrow Transplantation Report. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1522-1525.	2.0	15
126	Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 173-179.	2.0	38

#	ARTICLE	IF	CITATIONS
127	Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma—, <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1740-1744.	2.0	52
128	EZH2 mutations are frequent and represent an early event in follicular lymphoma. <i>Blood</i> , 2013, 122, 3165-3168.	0.6	274
129	The use of interim 18F-fluorodeoxyglucose PET to guide therapy in lymphoma. <i>Future Oncology</i> , 2013, 9, 807-815.	1.1	3
130	The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1409-1414.	1.3	63
131	Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3100-3109.	0.8	206
132	Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. <i>Haematologica</i> , 2013, 98, 620-625.	1.7	12
133	Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. <i>British Journal of Haematology</i> , 2013, 162, 648-656.	1.2	29
134	Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. <i>British Journal of Haematology</i> , 2013, 163, 168-181.	1.2	50
135	The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. <i>Blood</i> , 2013, 122, 424-433.	0.6	49
136	Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. <i>Haematologica</i> , 2013, 98, 1014-1021.	1.7	98
137	Stem cell mobilization in HIV seropositive patients with lymphoma. <i>Haematologica</i> , 2013, 98, 1762-1768.	1.7	27
138	Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. <i>Journal of Clinical Oncology</i> , 2012, 30, 3848-3853.	0.8	107
139	An innovative joint approach to HIV and lymphoma care. <i>Sexually Transmitted Infections</i> , 2012, 88, 71-71.	0.8	1
140	Management of Localized-Stage Follicular Lymphoma: Changing the Paradigm?. <i>Journal of Clinical Oncology</i> , 2012, 30, 3328-3329.	0.8	6
141	Interim fluoro-2-deoxy-D-glucose PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. <i>Aids</i> , 2012, 26, 861-865.	1.0	18
142	HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. <i>Journal of Clinical Oncology</i> , 2012, 30, 4111-4116.	0.8	145
143	Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1036-1043.e1.	2.0	15
144	Human immunodeficiency virus-associated plasmablastic lymphoma. <i>Cancer</i> , 2012, 118, 5270-5277.	2.0	147

#	ARTICLE	IF	CITATIONS
145	Guidelines on the investigation and management of follicular lymphoma. British Journal of Haematology, 2012, 156, 446-467.	1.2	58
146	Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intentionâ€toâ€treat analysis. British Journal of Haematology, 2012, 157, 201-204.	1.2	9
147	CNS Lymphoma in the Immunocompromised Host. , 2012, , 171-179.		0
148	The Clinical Course of Patients with Follicular Lymphoma in the Rituximab Era: A Paradigm Shift. Blood, 2012, 120, 1580-1580.	0.6	1
149	Evaluation of Quality of Biomarker Data Capture by Peripheral Sites in an International, Cooperative Study: Analysis of 104 Cases From the T-Cell Project.. Blood, 2012, 120, 2650-2650.	0.6	3
150	Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma. Blood, 2012, 120, 145-145.	0.6	0
151	Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A CIBMTR Analysis. Blood, 2012, 120, 473-473.	0.6	8
152	SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood, 2011, 117, 3147-3150.	0.6	17
153	Serum selenium concentration at diagnosis and outcome in patients with haematological malignancies. British Journal of Haematology, 2011, 154, 448-456.	1.2	20
154	The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia, 2011, 25, 551-555.	3.3	23
155	EZH2 Y641 mutations in follicular lymphoma. Leukemia, 2011, 25, 726-729.	3.3	132
156	Prognostic factors in patients with HIVâ€associated peripheral Tâ€cell lymphoma: A multicenter study. American Journal of Hematology, 2011, 86, 256-261.	2.0	42
157	Transformation of Indolent B-Cell Lymphomas. Journal of Clinical Oncology, 2011, 29, 1827-1834.	0.8	164
158	Use of Zidovudine and Interferon Alfa With Chemotherapy Improves Survival in Both Acute and Lymphoma Subtypes of Adult T-Cell Leukemia/Lymphoma. Journal of Clinical Oncology, 2011, 29, 4696-4701.	0.8	68
159	The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years. Blood, 2011, 118, 1593-1593.	0.6	4
160	A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL). Blood, 2011, 118, 499-499.	0.6	14
161	Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2011, 118, 501-501.	0.6	1
162	T-Cell Lymphomas in South America and Europe. Revista Brasileira De Hematologia E Hemoterapia, 2011, 34, 42-47.	0.7	38

#	ARTICLE	IF	CITATIONS
163	HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era,. Blood, 2011, 118, 3646-3646.	0.6	0
164	HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study. Blood, 2011, 118, 1589-1589.	0.6	1
165	Neither the FLIPI Nor the FLIPI2 Accurately Segregates Low- Risk From Intermediate- Risk Follicular Lymphoma Patients in Terms of Progression-Free Survival. Blood, 2011, 118, 2663-2663.	0.6	0
166	Molecular signatures in the diagnosis and management of follicular lymphoma. Current Opinion in Hematology, 2010, 17, 333-340.	1.2	8
167	Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. Aids, 2010, 24, 851-856.	1.0	54
168	Weekly <i>versus</i> twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. British Journal of Haematology, 2010, 151, 346-353.	1.2	63
169	Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. Haematologica, 2010, 95, 1130-1135.	1.7	10
170	Maintenance rituximab for relapsed follicular lymphoma. Nature Reviews Clinical Oncology, 2010, 7, 677-678.	12.5	1
171	Follicular lymphoma: managing an indolent malignancy. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0,784314 rgBT /Ove	0.2	0
172	Allogeneic Hematopoietic Cell Transplantation (AHCT) for Primary Cutaneous T Cell Lymphoma (CTCL): a Center for International Blood and Marrow Transplant Research (CIBMTR) Review. Blood, 2010, 116, 364-364.	0.6	3
173	Low dose continuous chemotherapy (LD56): an active treatment with low toxicity for patients with recurrent/refractory lymphoma not eligible for intensive salvage therapy. British Journal of Haematology, 2009, 147, 408-410.	1.2	1
174	Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. British Journal of Haematology, 2009, 147, 719-728.	1.2	40
175	Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood, 2009, 113, 3553-3557.	0.6	129
176	Patterns of Outcome Following Recurrence in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Long Follow-up From a Single Centre.. Blood, 2009, 114, 2921-2921.	0.6	0
177	Follicular lymphomas. Critical Reviews in Oncology/Hematology, 2008, 66, 248-261.	2.0	44
178	Lymphoplasmacytic lymphomaâ€“Waldenstrom's macroglobulinemia. Critical Reviews in Oncology/Hematology, 2008, 67, 172-185.	2.0	75
179	British HIV Association guidelines for HIV-associated malignancies 2008. HIV Medicine, 2008, 9, 336-388.	1.0	158
180	Oncologic, Endocrine & Metabolic Emerging drugs in B-cell non-Hodgkin's lymphoma. Expert Opinion on Emerging Drugs, 2008, 13, 323-343.	1.0	1

#	ARTICLE	IF	CITATIONS
181	Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. <i>Blood</i> , 2008, 111, 1085-1093.	0.6	107
182	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. <i>Haematologica</i> , 2008, 93, 207-214.	1.7	24
183	Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Associated Burkitt's Lymphoma (BL). <i>Blood</i> , 2008, 112, 3612-3612.	0.6	0
184	Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma.. <i>Blood</i> , 2008, 112, 3251-3251.	0.6	0
185	Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2426-2433.	0.8	348
186	Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease. <i>Annals of Internal Medicine</i> , 2007, 147, 836.	2.0	162
187	Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. <i>Blood</i> , 2007, 110, 4132-4133.	0.6	37
188	Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein Size. <i>Mayo Clinic Proceedings</i> , 2007, 82, 428-434.	1.4	76
189	Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. <i>Leukemia</i> , 2007, 21, 2324-2331.	3.3	138
190	Rituximab induces long-term remissions in patients with HIV-associated multicentric Castleman's disease. <i>Journal of Clinical Oncology</i> , 2007, 25, 8049-8049.	0.8	0
191	The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. <i>Annals of Oncology</i> , 2006, 17, 1539-1545.	0.6	107
192	Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. <i>European Journal of Haematology</i> , 2006, 76, 58-63.	1.1	36
193	Follicular Lymphoma. , 2006, , 348-373.		1
194	Isolated Brain Parenchyma Relapse of Non-Hodgkin's Lymphoma (NHL): A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).. <i>Blood</i> , 2006, 108, 2026-2026.	0.6	2
195	Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. <i>Annals of Oncology</i> , 2005, 16, 1508-1513.	0.6	46
196	Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. <i>Journal of Clinical Oncology</i> , 2005, 23, 2797-2804.	0.8	253
197	Bortezomib-Induced Severe Hepatitis in Multiple Myeloma. <i>Archives of Internal Medicine</i> , 2005, 165, 464.	4.3	42
198	Secondary Central Nervous System Lymphoma: Risk Factors and Prophylaxis. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 751-763.	0.9	22

#	ARTICLE	IF	CITATIONS
199	Risk and Clinical Implications of Transformation of Follicular Lymphoma (FL) to Diffuse Large Cell B-Cell Lymphoma (tFL).. Blood, 2005, 106, 602-602.	0.6	1
200	Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Annals of Oncology, 2004, 15, 1484-1489.	0.6	66
201	Malignant transformation in IgM monoclonal gammopathy of undetermined significance. Seminars in Oncology, 2003, 30, 178-181.	0.8	17
202	Smoldering multiple myeloma: natural history and recognition of an evolving type. British Journal of Haematology, 2003, 123, 631-636.	1.2	119
203	Incidence and Clinical Significance of Bcl-2 / IgH Rearrangements in Follicular Lymphoma. Leukemia and Lymphoma, 2003, 44, 71-76.	0.6	37
204	Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Annals of Oncology, 2002, 13, 523-530.	0.6	42
205	Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2002, 117, 387-389.	1.2	7
206	Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab. Annals of Hematology, 2001, 80, 479-481.	0.8	10
207	Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. British Journal of Haematology, 2001, 113, 422-424.	1.2	73
208	Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. British Journal of Haematology, 2001, 115, 575-582.	1.2	222
209	Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer, 2001, 91, 1557-1562.	2.0	22
210	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148.		17
211	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer, 2000, 88, 2142-8.	2.0	5
212	Acute Lymphoid Leukemia Following Polycythemia Vera. Leukemia and Lymphoma, 1999, 32, 395-398.	0.6	11
213	“Lymphoid” blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. British Journal of Haematology, 1998, 100, 129-134.	1.2	79
214	IMPAIRED PRODUCTION OF INTERLEUKIN 6 AND TUMOUR NECROSIS FACTOR β IN WHOLE BLOOD CELL CULTURES OF PATIENTS WITH MULTIPLE MYELOMA. Cytokine, 1998, 10, 993-996.	1.4	9
215	Renal Failure in Multiple Myeloma. Archives of Internal Medicine, 1998, 158, 1889.	4.3	328
216	Pyoderma Gangrenosum Triggered by β -Interferon in a Patient with Chronic Granulocytic Leukemia. Leukemia and Lymphoma, 1998, 30, 199-202.	0.6	41

#	ARTICLE	IF	CITATIONS
217	Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. European Journal of Haematology, 1998, 61, 59-64.	1.1	11